Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications

The therapeutic dominance of semaglutide in managing diabetes, obesity, and cardio-kidney-metabolic diseases has spurred an influx of generics, biosimilars, and compounded pharmacosimilars. However, shared nomenclature does not guarantee therapeutic equivalence. This analysis introduces the ABCDE framework (author-proposed conceptual checklist) to differentiate reference r-DNA semaglutide from synthetic or informally marketed copies. Evaluation rests on five pillars: (A) approved status, where regulatory authorization does not inherently imply interchangeability; (B) bioavailability, noting that identical exposure metrics may mask divergent impurity profiles and immunogenic risks; (C) consistency, highlighting that recombinant versus synthetic manufacturing can alter peptide stability and aggregation; (D) drug-device performance, with standardized pens helping to mitigate dosing errors that may occur with multidose vials; and (E) evidence, emphasizing that the robust clinical data from the SUSTAIN/STEP/SELECT programs are not transferable to copies. Consequently, we suggest that clinicians may find it useful to weigh product-specific evidence over label similarity when evaluating pharmacosimilars, using the ABCDE domains as a conceptual checklist (author-proposed mnemonic). Until stronger product-specific comparability evidence is available for alternative products, many clinicians may reasonably view reference semaglutide as the best-characterized option.